Humana maintains a conservative capital structure with a debt-to-equity ratio of 0.66 and a current ratio of 1.77, indicating adequate short-term liquidity coverage. The company holds $4.95 billion…
ResMed maintains a highly conservative capital structure with a debt-to-equity ratio of 0.04 and a current ratio of 3.01, indicating strong short-term liquidity coverage. The balance sheet holds $1…
Stryker maintains a leveraged capital structure with $14.19 billion in long-term debt against $3.39 billion in cash and equivalents, resulting in a negative net cash position. The debt-to-equity ra…
UnitedHealth Group maintains a capital structure characterized by significant leverage, with long-term debt of $71.44 billion against total equity of $103.90 billion, resulting in a debt-to-equity…
Quantum-Si maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a robust current ratio of 12.6, supported by $36.2 million in cash and equivalents and $154.2 million in to…
Elevance Health, Inc. (ELV) is currently classified as Commercial Banks within Banks (Financials). Classification confidence: 0.81 (rule-based classification). Capital structure on the latest snaps…
Envoy Medical, Inc. (COCH) is currently classified as Commercial Banks within Banks (Financials). Classification confidence: 0.81 (rule-based classification). Capital structure on the latest snapsh…
Cencora, Inc. (COR) is currently classified as Commercial Banks within Banks (Financials). Classification confidence: 0.81 (rule-based classification). Capital structure on the latest snapshot: tot…
Aardvark Therapeutics maintains a pristine balance sheet with zero debt and a current ratio of 8.06, indicating exceptional short-term liquidity. The company holds $62.4 million in cash and equival…
AbbVie’s capital structure is characterized by significant leverage and negative shareholders' equity, resulting in a debt-to-equity ratio of -9.7 and a return on equity of -0.6349. The balance she…
AbCellera maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a robust current ratio of 14.05, indicating strong short-term liquidity coverage. The balance sheet holds $7…
Arbutus Biopharma maintains a highly liquid balance sheet with $23.7 million in cash and equivalents and $71.5 million in current marketable securities, totaling $95.2 million in liquid assets. Tot…
ACME UNITED CORP maintains a conservative capital structure with a debt-to-equity ratio of 0.28 and a strong current ratio of 4.57, indicating ample short-term liquidity coverage. The company holds…
Aethlon Medical maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 3.85, indicating strong short-term liquidity coverage. The company holds $5.03 mill…
Agenus maintains a negative equity position of $221.2 million against total assets of $186.5 million, resulting in a debt-to-equity ratio of -0.14. The balance sheet shows $35.0 million in cash and…
Alnylam maintains a robust liquidity position with $1.71 billion in cash and equivalents and a current ratio of 3.05. The balance sheet shows total assets of $5.56 billion against total liabilities…
Altimmune maintains a highly liquid balance sheet with $97.6 million in cash and equivalents against $51.6 million in total liabilities, resulting in a current ratio of 29.56 and a debt-to-equity r…
ANI Pharmaceuticals maintains a conservative capital structure with a debt-to-equity ratio of 0.54 and a current ratio of 3.12, indicating strong short-term liquidity coverage. The balance sheet ho…
Annexon maintains a strong liquidity position with $175.2 million in cash and equivalents against total liabilities of $58.4 million, resulting in a current ratio of 6.35 and zero debt-to-equity. T…
Alto Neuroscience maintains a highly liquid balance sheet, holding $263.8 million in cash and equivalents against total liabilities of $32.9 million. The current ratio stands at 20.52, indicating s…
Apyx Medical maintains a capital structure characterized by high leverage and significant liquidity constraints. Total long-term debt stands at $35.1 million against total equity of $12.8 million,…
Arcturus Therapeutics maintains a strong liquidity position with $211.4 million in cash and equivalents against total liabilities of $54.0 million, resulting in a current ratio of 6.31 and zero deb…
Armata Pharmaceuticals exhibits a distressed capital structure with negative total equity of $-311.6 million against total assets of $69.8 million. The balance sheet shows total liabilities of $381…
Arcutis maintains a capital structure characterized by significant leverage relative to equity, with a debt-to-equity ratio of 0.58 and total liabilities of $270.4 million against $189.6 million in…
AtaiBeckley maintains a capital structure characterized by high leverage relative to equity, with short-term debt of $166.8 million against total equity of $198.7 million, resulting in a debt-to-eq…
ATOSSA THERAPEUTICS maintains a debt-free capital structure with $31.7 million in cash and equivalents against $7.5 million in total liabilities, resulting in a current ratio of 4.92 and a debt-to-…
AtriCure maintains a conservative capital structure with $146.2 million in cash and equivalents against $61.0 million in long-term debt, resulting in a low debt-to-equity ratio of 0.12. The balance…
HeartBeam maintains a fragile capital structure characterized by high liquidity risk and negative equity returns. The company holds $2.04 million in cash and equivalents against $3.29 million in to…
Bausch & Lomb maintains a capital structure characterized by significant leverage, with long-term debt of $5.05 billion and short-term debt of $28 million against total equity of $6.38 billion. The…
CRYO CELL INTERNATIONAL INC (CCEL) is currently classified as Commercial Banks within Banks (Financials). Classification confidence: 0.81 (rule-based classification). Capital structure on the lates…
Cadiz Inc. maintains a highly leveraged capital structure with total liabilities of $130.5 million against total equity of $15.6 million, resulting in a debt-to-equity ratio of 5.48. The balance sh…
Creative Medical Technology Holdings maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 19.69, indicating strong short-term liquidity coverage relativ…
Cognition Therapeutics maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 5.92, indicating strong short-term liquidity coverage. The balance sheet hol…
Celldex maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a robust current ratio of 8.92, indicating strong short-term liquidity coverage. The balance sheet holds $357.…
Centene maintains a capital structure supported by $21.26 billion in cash and equivalents against $16.31 billion in long-term debt and $63 million in short-term debt, resulting in a debt-to-equity…
Cocrystal Pharma maintains a debt-free capital structure with a debt-to-equity ratio of 0.0, supported by $7.025 million in cash and equivalents against total liabilities of $3.31 million. The curr…
Co-Diagnostics maintains a debt-free capital structure with a debt-to-equity ratio of 0.0. The balance sheet holds $8.23 million in cash and equivalents against $5.46 million in total liabilities,…
Catalyst Pharmaceuticals maintains a fortress balance sheet with $755.9 million in cash and equivalents against total liabilities of $134.9 million, resulting in a debt-to-equity ratio of 0.0 and a…
Cardiff Oncology operates with a capital structure characterized by zero debt and a current ratio of 3.27, indicating strong short-term liquidity coverage relative to liabilities. The company holds…
Corvus Pharmaceuticals maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a robust current ratio of 19.81, indicating strong short-term liquidity coverage. The balance s…
CytomX maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a robust current ratio of 10.38, indicating strong short-term liquidity coverage. Total equity stands at $319.9…
Delcath Systems maintains a highly liquid balance sheet with $41.3 million in cash and equivalents against total liabilities of $12.1 million, resulting in a current ratio of 11.24 and zero debt-to…
Damora Therapeutics maintains a robust liquidity position with $532.9 million in cash and equivalents against total liabilities of $23.8 million, resulting in a current ratio of 22.48 and a debt-to…
DexCom maintains a robust liquidity position with $1.105 billion in cash and equivalents and a current ratio of 1.73. The balance sheet shows total assets of $6.455 billion against total liabilitie…
Edgewise Therapeutics maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a robust current ratio of 22.61, indicating strong short-term liquidity coverage. The balance sh…
Exelixis maintains a robust capital structure characterized by zero debt and a current ratio of 3.26, indicating strong short-term liquidity coverage. The balance sheet holds $226.2 million in cash…
GeoVax Labs maintains a fragile capital structure characterized by high liquidity risk and substantial dilution pressure. The company holds $1.27 million in cash and equivalents against total liabi…
Hyperion DeFi maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 1.97, indicating adequate short-term liquidity coverage. The balance sheet holds $70.…
Incyte maintains a robust capital structure characterized by zero debt-to-equity and a current ratio of 3.68, indicating strong short-term liquidity. The balance sheet holds $3.46 billion in cash a…
Invivyd maintains a strong liquidity position with $184.2 million in cash and equivalents against $38.7 million in total liabilities, resulting in a current ratio of 6.47 and a debt-to-equity ratio…
Johnson & Johnson maintains a capital structure characterized by significant leverage, with total debt comprising $37.5 billion in long-term obligations and $17.5 billion in short-term debt against…
Eli Lilly maintains a capital structure characterized by substantial leverage, with long-term debt of $39.37 billion against total equity of $31.20 billion, resulting in a debt-to-equity ratio of 1…
Lucid Diagnostics maintains a capital structure defined by high cash reserves relative to its minimal equity base. As of Q1 2026, the company holds $47.3 million in cash and equivalents against tot…
Myriad Genetics maintains a capital structure characterized by significant leverage relative to its equity base, with total debt of $179.7 million (comprising $120.3 million in long-term debt and $…
MYOMO maintains a current ratio of 2.73, supported by $11.4 million in cash and equivalents against $2.7 million in short-term debt, resulting in a low debt-to-equity ratio of 0.3. However, the com…
OPKO Health maintains a conservative capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 3.61, indicating strong short-term liquidity coverage. The balance sheet holds $331.…
Pacific Biosciences maintains a capital structure defined by negligible short-term debt and a substantial cash position of $56.3 million, resulting in a current ratio of 5.65. However, total liabil…
Phathom Pharmaceuticals maintains a negative equity position of $336.96 million against total liabilities of $642.08 million as of Q1 2026. The balance sheet includes $180.90 million in cash and eq…
ProPhase Labs presents a distressed capital structure with total liabilities of $59.3 million exceeding total assets of $58.7 million, resulting in a negative equity position of $0.6 million. The c…
Rani Therapeutics maintains a debt-free capital structure with zero long-term and short-term debt, supported by $9.6 million in cash and equivalents against total assets of $51.9 million. The balan…
Regeneron maintains a robust capital structure characterized by high liquidity and low leverage. The company holds $2.46 billion in cash and equivalents against $1.99 billion in long-term debt, res…
Rafael Holdings maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 3.16, indicating strong short-term liquidity coverage. The company holds $30.5 mill…
Rein Therapeutics maintains a fragile capital structure characterized by high liquidity risk and significant dilution pressure. As of Q1 2026, the company holds $4.4 million in cash and equivalents…
Senti Biosciences operates with a fragile capital structure, holding $8.94 million in cash and equivalents against total liabilities of $35.68 million and total equity of $2.57 million. The current…
TScan Therapeutics maintains a strong liquidity position with $128.1 million in cash and equivalents against total liabilities of $105.1 million, resulting in a current ratio of 6.65. The balance s…
Telomir Pharmaceuticals maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 7.0, indicating strong short-term liquidity coverage. The company holds $75…
Tango Therapeutics maintains a robust balance sheet with $157.8 million in cash and equivalents against $44.3 million in total liabilities, resulting in a debt-to-equity ratio of 0.0 and a current…
Tempest Therapeutics operates with a highly leveraged equity structure relative to its asset base, holding $1.8 million in cash and equivalents against $9.9 million in total liabilities, resulting…
Traws Pharma maintains a negative equity position of -$5.3 million against total liabilities of $13.5 million, resulting in a debt-to-equity ratio of -0.0 and a return on equity of -1.73. The balan…
Viking Therapeutics maintains a pristine balance sheet with zero debt and a current ratio of 5.72, indicating strong short-term liquidity coverage. The company holds $118.1 million in cash and equi…
Vivos Therapeutics presents a distressed capital structure characterized by negative total equity of -$1.14 million and a current ratio of 0.27, indicating that current liabilities significantly ex…
Xencor maintains a capital structure characterized by low leverage and high liquidity relative to its asset base. The company holds $14.2 million in cash and equivalents against $82.1 million in lo…
Contineum Therapeutics maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 37.17, reflecting substantial liquidity relative to liabilities. Total asset…
Precision BioSciences maintains a robust liquidity position with $99.4 million in cash and equivalents against total liabilities of $67.8 million, resulting in a current ratio of 14.02 and a debt-t…
Travere Therapeutics maintains a debt-free capital structure with a debt-to-equity ratio of 0.0, supported by $78.4 million in cash and equivalents and a current ratio of 3.13. The company holds $1…
AngioDynamics maintains a conservative capital structure with zero debt-to-equity and a current ratio of 2.19, supported by $53.9 million in cash and equivalents against total liabilities of $96.3…
Alphatec Holdings maintains a highly leveraged capital structure with negative total equity of -$5.3 million against total assets of $799.5 million. The balance sheet carries $507.9 million in long…
Baxter International maintains a capital structure characterized by significant leverage, with long-term debt of $9.47 billion against total equity of $6.21 billion, resulting in a debt-to-equity r…
BioXcel Therapeutics, Inc. (BTAI) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.78 (rule-based classification). Capital structure on t…
Oncolytics Biotech maintains a negative equity position of $5.13 million against total liabilities of $13.29 million, resulting in a debt-to-equity ratio of -0.0 and a return on equity of 1.80x. Th…
Syndax Pharmaceuticals maintains a highly leveraged capital structure with a debt-to-equity ratio of 8.41, driven by $350 million in short-term debt against $41.6 million in total equity. Despite t…
BNB PLUS CORP. (BNBX) is currently classified as Asset Management & Custody Services within Investment Management & Fund Operators (Financials). Classification confidence: 0.77 (rule-based classifi…
Cytosorbents Corp (CTSO) is currently classified as Medical Devices within Medical Equipment & Supplies (Healthcare). Classification confidence: 0.70 (rule-based classification). Capital structure…
Actinium Pharmaceuticals maintains a strong liquidity position with a current ratio of 5.89 and $42.1 million in cash and equivalents against total liabilities of $43.1 million. The balance sheet s…
CalciMedica maintains a negative equity position of -$1.1 million against total liabilities of $9.7 million, resulting in a debt-to-equity ratio of -0.0 and a return on equity of -4.51%. The balanc…
Phio Pharmaceuticals maintains a debt-free capital structure with $17.0 million in cash and equivalents against $0.95 million in total liabilities, resulting in a current ratio of 14.43 and a debt-…
Simulations Plus maintains a pristine balance sheet with zero debt and a current ratio of 5.54, supported by $35.3 million in cash and equivalents. The company generates strong operating cash flow…
MCKESSON CORP (MCK) is currently classified as Application Software within Software (Technology). Classification confidence: 0.66 (rule-based classification). Capital structure on the latest snapsh…
GE HealthCare Technologies Inc. (GEHC) is currently classified as Application Software within Software (Technology). Classification confidence: 0.66 (rule-based classification). Capital structure o…
Esperion maintains a negative equity position of $307.9 million against total liabilities of $770.5 million, resulting in a debt-to-equity ratio of -0.0. The balance sheet holds $156.2 million in c…
BIOMARIN PHARMACEUTICAL INC (BMRN) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.78 (rule-based classification). Capital structure on…
InspireMD, Inc. (NSPR) is currently classified as Exploration & Production within Oil & Gas Exploration & Production (Energy). Classification confidence: 0.92 (rule-based classification). Capital s…
TG THERAPEUTICS, INC. (TGTX) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.98 (rule-based classification). Capital structure on the la…
Oncology Institute, Inc. reports a negative equity position of $-16.3 million against total liabilities of $184.5 million and total assets of $168.2 million as of Q1 2026. The balance sheet is heav…
UFP TECHNOLOGIES INC (UFPT) is currently classified as Exploration & Production within Oil & Gas Exploration & Production (Energy). Classification confidence: 0.92 (rule-based classification). Capi…
VIEMED HEALTHCARE, INC. (VMD) is currently classified as Multiline Insurance & Brokers within Insurance (Financials). Classification confidence: 0.77 (rule-based classification). Capital structure…
VERTEX PHARMACEUTICALS INC / MA (VRTX) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.78 (rule-based classification). Capital structure…
Wellgistics Health presents a distressed capital structure characterized by negative total equity of $-15.1 million and a current ratio of 0.09, indicating severe liquidity constraints. Total liabi…
ACADIA PHARMACEUTICALS INC (ACAD) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.98 (rule-based classification). Capital structure on t…
ClearPoint Neuro, Inc. (CLPT) is currently classified as Medical Devices within Medical Equipment & Supplies (Healthcare). Classification confidence: 0.70 (rule-based classification). Capital struc…
CRISPR Therapeutics AG (CRSP) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.93 (rule-based classification). Capital structure on the l…
Krystal Biotech, Inc. (KRYS) is currently classified as Biotechnology within Biotechnology (Healthcare). Classification confidence: 0.89 (rule-based classification). Capital structure on the latest…
SI-BONE, Inc. (SIBN) is currently classified as Medical Devices within Medical Equipment & Supplies (Healthcare). Classification confidence: 0.82 (rule-based classification). Capital structure on t…
Turning Point Brands, Inc. (TPB) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.66 (rule-based classification). Capital structure on th…
Zimmer Biomet maintains a leveraged capital structure with total debt of $7.47 billion against $12.67 billion in equity, resulting in a debt-to-equity ratio of 0.59. The company holds $424.2 millio…
ABBOTT LABORATORIES (ABT) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.78 (rule-based classification). Capital structure on the lates…
PFIZER INC (PFE) is currently classified as Biotechnology within Biotechnology (Healthcare). Classification confidence: 0.81 (rule-based classification). Capital structure on the latest snapshot: t…
BIO-PATH HOLDINGS, INC. exhibits a severely distressed capital structure, reporting negative total equity of $-8.49 million against total liabilities of $9.16 million as of Q1 2026. The balance she…
DANAHER CORP /DE/ (DHR) is currently classified as Exploration & Production within Oil & Gas Exploration & Production (Energy). Classification confidence: 0.62 (rule-based classification). Capital…
Evolent Health, Inc. (EVH) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.81 (rule-based classification). Capital structure on the late…
Rocket One Inc. maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 3.39, indicating strong short-term liquidity coverage. The company holds $4.05 mill…
Azenta, Inc. (AZTA) is currently classified as Industrial Machinery within Industrial Machinery & Equipment (Industrials). Classification confidence: 0.70 (rule-based classification). Capital struc…
Aspira Women's Health Inc. presents a distressed capital structure characterized by negative total equity of $6.2 million and a working capital deficit of $1.8 million as of Q1 2026. The company ho…
EyePoint maintains a strong liquidity position with $77.7 million in cash and equivalents and $144.8 million in marketable securities, totaling $222.5 million in liquid assets [doc:10-Q false --12-…
BRISTOL MYERS SQUIBB CO (BMY) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.98 (rule-based classification). Capital structure on the l…
Cigna Group (CI) is currently classified as Multiline Insurance & Brokers within Insurance (Financials). Classification confidence: 0.92 (rule-based classification). Capital structure on the latest…
Amneal Pharmaceuticals, Inc. (AMRX) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.98 (rule-based classification). Capital structure on…
BridgeBio Pharma, Inc. (BBIO) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.98 (rule-based classification). Capital structure on the l…
COMMUNITY HEALTH SYSTEMS INC (CYH) is currently classified as Medical Devices within Medical Equipment & Supplies (Healthcare). Classification confidence: 0.97 (rule-based classification). Capital…
Scilex Holding Co (SCLX) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.78 (rule-based classification). Capital structure on the latest…
Aura Biosciences, Inc. (AURA) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.93 (rule-based classification). Capital structure on the l…
Avanos Medical maintains a conservative capital structure with a debt-to-equity ratio of 0.01 and a current ratio of 2.48, indicating strong short-term liquidity coverage. The balance sheet holds $…
Bone Biologics maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 16.09, indicating strong short-term liquidity coverage. The company holds total asse…
Biohaven maintains a debt-free capital structure with $273.1 million in cash and equivalents against $336.9 million in total liabilities, resulting in a current ratio of 7.41 and zero debt-to-equit…
Cellectar Biosciences maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 1.9, indicating adequate short-term liquidity coverage. The company holds $8.…
CYPHERPUNK TECHNOLOGIES INC. (CYPH) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.78 (rule-based classification). Capital structure on…
Elicio Therapeutics, Inc. (ELTX) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.98 (rule-based classification). Capital structure on th…
InMed Pharmaceuticals maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 3.11, indicating strong short-term liquidity coverage. The company holds $5.1…
Lexaria Bioscience maintains a highly liquid balance sheet with $5.1 million in cash and equivalents against total liabilities of $277,000, resulting in a current ratio of 26.88 and zero debt-to-eq…
Liminatus Pharma presents a distressed capital structure characterized by negative total equity of -$132,596 and a debt-to-equity ratio of -10.88 as of Q1 2026. The company holds $1,442,500 in shor…
Tarsus Pharmaceuticals, Inc. (TARS) is currently classified as Biotechnology within Biotechnology (Healthcare). Classification confidence: 0.93 (rule-based classification). Capital structure on the…
WEST PHARMACEUTICAL SERVICES INC (WST) is currently classified as Exploration & Production within Oil & Gas Exploration & Production (Energy). Classification confidence: 0.77 (rule-based classifica…
ARDELYX, INC. (ARDX) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.98 (rule-based classification). Capital structure on the latest sna…
BOSTON SCIENTIFIC CORP (BSX) is currently classified as Medical Devices within Medical Equipment & Supplies (Healthcare). Classification confidence: 0.70 (rule-based classification). Capital struct…
ENANTA PHARMACEUTICALS INC (ENTA) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.78 (rule-based classification). Capital structure on t…
Ovid Therapeutics Inc. (OVID) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.93 (rule-based classification). Capital structure on the l…
CEL SCI CORP's capital structure is marked by a high debt-to-equity ratio of 0.83 and a current ratio of 0.6, indicating that current liabilities exceed current assets. The company's liquidity posi…
Palatin Technologies Inc has a liquidity position that appears robust, with a current ratio of 5.04 and cash and equivalents amounting to $10,159,494, which significantly exceeds its total liabilit…
Impact BioMedical Inc. has a highly leveraged capital structure with a current ratio of 0.22, indicating that its current liabilities significantly exceed its current assets. The company's liquidit…
ACHIEVE LIFE SCIENCES maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 2.62, indicating strong short-term liquidity coverage. The balance sheet hold…
SI's capital structure is characterized by a low debt-to-equity ratio of 0.11, indicating a conservative leverage profile. The company holds $11.49 million in cash and equivalents, but its operatin…
Alpha Pro Tech Ltd maintains a strong liquidity position with $16.88 million in cash and equivalents, and a current ratio of 19.81, indicating significant short-term financial flexibility. The comp…
Cellectis S.A. (CLLS) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.78 (rule-based classification). Capital structure on the latest sn…
Crinetics Pharmaceuticals, Inc. (CRNX) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.93 (rule-based classification). Capital structure…
ENvue Medical, Inc. (FEED) is currently classified as Medical Devices within Medical Equipment & Supplies (Healthcare). Classification confidence: 0.70 (rule-based classification). Capital structur…
The company's capital structure is characterized by a low debt-to-equity ratio of 0.01, indicating minimal leverage. Its liquidity position is supported by $2.77 million in cash and equivalents, wi…
Structure and Liquidity Picard Medical, Inc. has a negative total equity of -$1.45 million and a current ratio of 0.75, indicating that current liabilities exceed current assets. The company's liqu…
Capital structure and liquidity metrics are unavailable for assessment. The financial snapshot required to evaluate balance sheet strength, cash flow, and leverage ratios was not provided in the in…
We'll email you once when Handelsavisen goes live. No spam, no other use.
By signing up you agree to receive a single launch-day notification from Handelsavisen.